TLDR: Two Canadian patients with spinal cord injuries have successfully received Neuralink brain implants, enabling them to control computers with their thoughts. This groundbreaking development, powered by artificial intelligence, represents a significant step forward in assistive technology for individuals with severe mobility impairments.
In a significant medical and technological breakthrough, two Canadian patients, both approximately 30 years old and living with spinal cord injuries, have been implanted with Elon Musk’s Neuralink brain chip. This marks the first clinical trial of the wireless brain chip outside of the United States, aiming to assess its safety and effectiveness in allowing individuals to control external devices purely through thought. The procedures, led by neurosurgeon Dr. Andres Lozano at Toronto Western Hospital, part of the University Health Network, took place on August 27 and September 3, 2025, with patients reportedly able to leave the hospital the following morning.
The Neuralink system involves implanting electrodes into the motor area of the patient’s brain. These electrodes are designed to capture neuron signals, which are then decoded and translated into actions on an external device by sophisticated artificial intelligence. Dr. Lozano highlighted the immediate impact of the technology, stating, ‘The first patient was able to control a cursor by just thinking within minutes. It is extremely rapid. The signals are decoded and the artificial intelligence reads the signals and then translates them into movement on the cursor. They just think about it and it happens.’ This rapid adaptation allowed patients to move a computer cursor and even play video games almost immediately post-surgery.
While the current application focuses on cursor control, the long-term vision for Neuralink’s technology is far more ambitious. Dr. Lozano suggested that in the future, the device could enable users to ‘drive a car, you could drive your wheelchair, you could drive a robot.’ This potential for expanded control over various robotic and assistive technologies underscores the transformative promise of brain-computer interfaces (BCIs).
Also Read:
- Nvidia Unveils Jet-Nemotron and Nemotron Nano: A Leap in AI Model Efficiency
- OpenAI Collaborates with Broadcom for 2026 Launch of Custom AI Chip
However, experts also urge tempered expectations. Barry Munro, chief development officer of the Canadian Spinal Research Organization, who assisted with patient recruitment, emphasized that while encouraging, the technology is still in its preliminary stages. The Canadian trial is a crucial step to evaluate the device’s safety, with potential side effects including seizures, infections, or strokes, before any broader rollout. It’s also noted that Neuralink is not the sole player in the BCI field, with other companies like New York-based Synchron also conducting their own clinical trials, contributing to a rapidly evolving landscape of neuro-assistive technologies.
